<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860820</url>
  </required_header>
  <id_info>
    <org_study_id>103618</org_study_id>
    <nct_id>NCT01860820</nct_id>
  </id_info>
  <brief_title>The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema</brief_title>
  <official_title>The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <authority>Canada: Research Ethics Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, controlled trial involving kidney and kidney pancreas transplant
      patients. There will be 2 groups and patients will be randomized to one of the two; one will
      receive standard of care IPC or TED stockings to help with circulation, the other group will
      use the geko device which is a newer device with Health Canada approval. Clinical outcomes
      will be compared for those in each group and clinical differences between patients who
      receive routine medical therapy with IPC/TEDS versus the Geko device will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease in edema</measure>
    <time_frame>Within 30 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by patient weight and leg diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>3 and 6 days after transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be asked to complete a questionnaire at these time points to assess their satisfaction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Use of diuretics</measure>
    <time_frame>Within 30 days of transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diuretic use wil be tracked for participants in each of the arms to assess wither there is a difference.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Kidney Pancreas Transplant</condition>
  <condition>Edema</condition>
  <arm_group>
    <arm_group_label>Best Medical Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will follow standard post-transplant protocols with IPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Geko device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Geko device</intervention_name>
    <arm_group_label>Geko device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  At least 18 years old

          -  Undergoing kidney or kidney pancreas transplant surgery as the recipient

          -  Able and willing to provide written informed consent

          -  Absence of known peripheral vascular disease

          -  Body Mass Index of between 18 and 34

          -  Leg circumference at site of gekoâ„¢ device placement is 24&quot; or less

        Exclusion Criteria:

          -  History of deep vein thrombosis

          -  Temporary or permanent cardiac pacing

          -  Patient is pregnant

          -  Any patient which may be excluded by way of warnings in the Manufacturer's
             Instructions for Use

          -  Any patient who requires an ECG electrode applied on the leg for continuous
             monitoring throughout therapy

          -  Previous leg(s) amputation

          -  Presence of any of the following in the site of intended device placement: cancerous
             lesion, swollen or infected or inflamed areas or skin eruptions i.e. phlebitis,
             thrombophlebitis, varicose veins

          -  History or signs of haematological disorders (especially in relation to clotting or
             coagulation disorders) including presence or history of thrombus formation

          -  BMI index &gt;36

          -  Patients with any neurological disorder or disease that would interfere with proper
             assessment and or conduct of the trial

          -  History of implantable brain or other stimulator

          -  Patients who can not tolerate the stimulation from the GEKO device
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alp Sener, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute, London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alp Sener, MD</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>33352</phone_ext>
    <email>alp.sener@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alp Sener, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>33352</phone_ext>
      <email>alp.sener@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 22, 2013</lastchanged_date>
  <firstreceived_date>May 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Alp Sener</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IPC/TEDS</keyword>
  <keyword>Geko device</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
